Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Inserm · Institut Gustave Roussy · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,759
total citations
- FWCI
- 128.58
- Percentile
- 100%
- References
- 32
Citations per year
Authors
25Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Ipilimumab
- Internal medicine
- Clinical endpoint
- Adverse effect
- Refractory (planetary science)
- Cohort
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.